Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Anika Therapeutics (ANIK) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 682,310
  • Shares Outstanding, K 14,780
  • Annual Sales, $ 93,000 K
  • Annual Income, $ 30,760 K
  • 36-Month Beta 1.75
  • Price/Sales 7.38
  • Price/Book 3.23

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.38 +12.40%
on 11/03/16
47.18 -1.42%
on 12/01/16
+4.20 (+9.93%)
since 11/02/16
3-Month
41.38 +12.40%
on 11/03/16
49.00 -5.08%
on 09/06/16
-1.38 (-2.88%)
since 09/02/16
52-Week
35.07 +32.62%
on 01/28/16
54.96 -15.37%
on 07/05/16
+4.02 (+9.46%)
since 12/02/15

Most Recent Stories

More News
Cytori Scleroderma Study Two-Year Follow-Up Data Published

Cytori Therapeutics (CYTX) announced the publication of two year follow-up data from the scleroderma study.

Aimmune Closes Enrolment in Phase III Peanut Allergy Study

Aimmune Therapeutics, Inc. (AIMT) announced that it has completed global enrollment in the phase III PALISADE study on AR101

PhaseRx Soars on Orphan Drug Status for Rare Liver Disease

PhaseRx (PZRX) received Orphan Drug status from the FDA for PRX-OTC for the treatment of rare liver disorder.

Foamix Completes Enrolment in Phase III Acne Drug Studies

Foamix Pharmaceuticals Ltd. (FOMX) announced that it has completed patient enrollment in two phase III studies

Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial

Jazz Pharmaceuticals Public Limited Company (JAZZ) announced that its phase III study, evaluating JZP-110 has completed patient enrollment.

Zacks.com featured highlights: Chemours, Matador Resources, Best Buy, Anika Therapeutics and McDermott International

Zacks.com featured highlights: Chemours, Matador Resources, Best Buy, Anika Therapeutics and McDermott International

Navidea Inks Deal to to Sell Lymphoseek to Cardinal Health

Navidea Biopharmaceuticals, Inc (NAVB) announced that it has entered into a definitive agreement to sell its Lymphoseek product to Cardinal Health (CAH).

OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S.

OPKO Health, Inc. (OPK) announced the launch of its kidney drug Rayaldee (calcifediol).

Merck (MRK) Announces 2.2% Increase in Quarterly Dividend

Merck & Co., Inc, (MRK) recently announced a 2.2% hike in its quarterly dividend.

Glaxo Nucala Favorable in Rare Vasculitis Disease Study

Glaxo's (GSK) Nucala hit co-primary endpoints and all secondary endpoints in a phase III study in patients with eosinophilic granulomatosis with polyangiitis.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices that promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid, a naturally-occurring, biocompatible polymer found in the body. Due to...

See More

Support & Resistance

2nd Resistance Point 47.39
1st Resistance Point 46.95
Last Price 46.51
1st Support Level 46.22
2nd Support Level 45.93

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.